Cargando…
A phase II study of recombinant interferon-beta (r-hIFN-beta 1a) in combination with 5-fluorouracil (5-FU) in the treatment of patients with advanced colorectal carcinoma.
The combination of 5-fluorouracil (5-FU) and interferon-alpha (IFN-alpha) has reported activity in the treatment of advanced colorectal carcinoma. Laboratory studies of IFN-beta suggest that this agent may offer theoretical advantages over IFN-alpha in combination with 5-FU. A total of 27 patients w...
Autores principales: | , , , , , , , |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group|1
1997
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2063373/ https://www.ncbi.nlm.nih.gov/pubmed/9020490 |
_version_ | 1782137323285118976 |
---|---|
author | Joffe, J. K. Perren, T. J. Bradley, C. Primrose, J. Hallam, S. Ward, U. Illingworth, J. M. Selby, P. J. |
author_facet | Joffe, J. K. Perren, T. J. Bradley, C. Primrose, J. Hallam, S. Ward, U. Illingworth, J. M. Selby, P. J. |
author_sort | Joffe, J. K. |
collection | PubMed |
description | The combination of 5-fluorouracil (5-FU) and interferon-alpha (IFN-alpha) has reported activity in the treatment of advanced colorectal carcinoma. Laboratory studies of IFN-beta suggest that this agent may offer theoretical advantages over IFN-alpha in combination with 5-FU. A total of 27 patients with advanced or recurrent colorectal carcinoma were treated in a non-randomized open phase II study with a combination of 5-fluorouracil (750 mg m(-1) daily for 5 days as a continuous intravenous (i.v.) infusion followed, from day 15, by i.v. bolus 750 mg m(-2) every 7 days) and recombinant interferon-beta [r-hIFN-beta-1a; 9 MIU (total dose) by subcutaneous injection from day 1 on every Monday, Wednesday and Friday throughout the treatment period]. Toxicity was less than that seen with this schedule of 5-FU in combination with IFN-alpha. Among 21 evaluable patients, four objective responses were seen. Recombinant human interferon-beta-1a in combination with 5-FU is an acceptable regimen in terms of toxicity. However, the study did not demonstrate a superior response rate when compared with previous reports of treatment with 5-FU alone or in combination with IFN-alpha. |
format | Text |
id | pubmed-2063373 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 1997 |
publisher | Nature Publishing Group|1 |
record_format | MEDLINE/PubMed |
spelling | pubmed-20633732009-09-10 A phase II study of recombinant interferon-beta (r-hIFN-beta 1a) in combination with 5-fluorouracil (5-FU) in the treatment of patients with advanced colorectal carcinoma. Joffe, J. K. Perren, T. J. Bradley, C. Primrose, J. Hallam, S. Ward, U. Illingworth, J. M. Selby, P. J. Br J Cancer Research Article The combination of 5-fluorouracil (5-FU) and interferon-alpha (IFN-alpha) has reported activity in the treatment of advanced colorectal carcinoma. Laboratory studies of IFN-beta suggest that this agent may offer theoretical advantages over IFN-alpha in combination with 5-FU. A total of 27 patients with advanced or recurrent colorectal carcinoma were treated in a non-randomized open phase II study with a combination of 5-fluorouracil (750 mg m(-1) daily for 5 days as a continuous intravenous (i.v.) infusion followed, from day 15, by i.v. bolus 750 mg m(-2) every 7 days) and recombinant interferon-beta [r-hIFN-beta-1a; 9 MIU (total dose) by subcutaneous injection from day 1 on every Monday, Wednesday and Friday throughout the treatment period]. Toxicity was less than that seen with this schedule of 5-FU in combination with IFN-alpha. Among 21 evaluable patients, four objective responses were seen. Recombinant human interferon-beta-1a in combination with 5-FU is an acceptable regimen in terms of toxicity. However, the study did not demonstrate a superior response rate when compared with previous reports of treatment with 5-FU alone or in combination with IFN-alpha. Nature Publishing Group|1 1997 /pmc/articles/PMC2063373/ /pubmed/9020490 Text en https://creativecommons.org/licenses/by/4.0/This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit https://creativecommons.org/licenses/by/4.0/. |
spellingShingle | Research Article Joffe, J. K. Perren, T. J. Bradley, C. Primrose, J. Hallam, S. Ward, U. Illingworth, J. M. Selby, P. J. A phase II study of recombinant interferon-beta (r-hIFN-beta 1a) in combination with 5-fluorouracil (5-FU) in the treatment of patients with advanced colorectal carcinoma. |
title | A phase II study of recombinant interferon-beta (r-hIFN-beta 1a) in combination with 5-fluorouracil (5-FU) in the treatment of patients with advanced colorectal carcinoma. |
title_full | A phase II study of recombinant interferon-beta (r-hIFN-beta 1a) in combination with 5-fluorouracil (5-FU) in the treatment of patients with advanced colorectal carcinoma. |
title_fullStr | A phase II study of recombinant interferon-beta (r-hIFN-beta 1a) in combination with 5-fluorouracil (5-FU) in the treatment of patients with advanced colorectal carcinoma. |
title_full_unstemmed | A phase II study of recombinant interferon-beta (r-hIFN-beta 1a) in combination with 5-fluorouracil (5-FU) in the treatment of patients with advanced colorectal carcinoma. |
title_short | A phase II study of recombinant interferon-beta (r-hIFN-beta 1a) in combination with 5-fluorouracil (5-FU) in the treatment of patients with advanced colorectal carcinoma. |
title_sort | phase ii study of recombinant interferon-beta (r-hifn-beta 1a) in combination with 5-fluorouracil (5-fu) in the treatment of patients with advanced colorectal carcinoma. |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2063373/ https://www.ncbi.nlm.nih.gov/pubmed/9020490 |
work_keys_str_mv | AT joffejk aphaseiistudyofrecombinantinterferonbetarhifnbeta1aincombinationwith5fluorouracil5fuinthetreatmentofpatientswithadvancedcolorectalcarcinoma AT perrentj aphaseiistudyofrecombinantinterferonbetarhifnbeta1aincombinationwith5fluorouracil5fuinthetreatmentofpatientswithadvancedcolorectalcarcinoma AT bradleyc aphaseiistudyofrecombinantinterferonbetarhifnbeta1aincombinationwith5fluorouracil5fuinthetreatmentofpatientswithadvancedcolorectalcarcinoma AT primrosej aphaseiistudyofrecombinantinterferonbetarhifnbeta1aincombinationwith5fluorouracil5fuinthetreatmentofpatientswithadvancedcolorectalcarcinoma AT hallams aphaseiistudyofrecombinantinterferonbetarhifnbeta1aincombinationwith5fluorouracil5fuinthetreatmentofpatientswithadvancedcolorectalcarcinoma AT wardu aphaseiistudyofrecombinantinterferonbetarhifnbeta1aincombinationwith5fluorouracil5fuinthetreatmentofpatientswithadvancedcolorectalcarcinoma AT illingworthjm aphaseiistudyofrecombinantinterferonbetarhifnbeta1aincombinationwith5fluorouracil5fuinthetreatmentofpatientswithadvancedcolorectalcarcinoma AT selbypj aphaseiistudyofrecombinantinterferonbetarhifnbeta1aincombinationwith5fluorouracil5fuinthetreatmentofpatientswithadvancedcolorectalcarcinoma AT joffejk phaseiistudyofrecombinantinterferonbetarhifnbeta1aincombinationwith5fluorouracil5fuinthetreatmentofpatientswithadvancedcolorectalcarcinoma AT perrentj phaseiistudyofrecombinantinterferonbetarhifnbeta1aincombinationwith5fluorouracil5fuinthetreatmentofpatientswithadvancedcolorectalcarcinoma AT bradleyc phaseiistudyofrecombinantinterferonbetarhifnbeta1aincombinationwith5fluorouracil5fuinthetreatmentofpatientswithadvancedcolorectalcarcinoma AT primrosej phaseiistudyofrecombinantinterferonbetarhifnbeta1aincombinationwith5fluorouracil5fuinthetreatmentofpatientswithadvancedcolorectalcarcinoma AT hallams phaseiistudyofrecombinantinterferonbetarhifnbeta1aincombinationwith5fluorouracil5fuinthetreatmentofpatientswithadvancedcolorectalcarcinoma AT wardu phaseiistudyofrecombinantinterferonbetarhifnbeta1aincombinationwith5fluorouracil5fuinthetreatmentofpatientswithadvancedcolorectalcarcinoma AT illingworthjm phaseiistudyofrecombinantinterferonbetarhifnbeta1aincombinationwith5fluorouracil5fuinthetreatmentofpatientswithadvancedcolorectalcarcinoma AT selbypj phaseiistudyofrecombinantinterferonbetarhifnbeta1aincombinationwith5fluorouracil5fuinthetreatmentofpatientswithadvancedcolorectalcarcinoma |